Evogen's Cognizance nabs new U.S. patent for diagnostic biomarkers for epilepsy

Oct. 10, 2018 7:20 AM ETBy: Mamta Mayani, SA News Editor
  • Cognizance Biomarkers, LLC, a wholly-owned subsidiary of Evogen, Inc., announces that the USPTO has issued a new patent providing further protection for its neuro-inflammatory biomarkers for the diagnosis, management and treatment of epileptic seizures.
  • U.S. Patent 9,772,335 is owned by the University of Pennsylvania and exclusively licensed to Cognizance. This is the second issued patent covering methods for detecting seizures and assessing the effectiveness of treatments for seizures using neuro-inflammatory biomarkers.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.